Skip to main content

Table 3 Progression of vitreous hemorrhage score during the study in Group B

From: Intravitreal bevacizumab (IVB) versus IVB in combination with pars plana vitrectomy for vitreous hemorrhage secondary to proliferative diabetic retinopathy: a randomized clinical trial

Group B Baseline 8 Weeks 16 Weeks 24 Weeks
Grade 0 0 31 31 30
Grade 1 1 1 1 1
Grade 2 11 0 0 0
Grade 3 23 3 3 4